| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| Other Sizes |
| Targets |
Isoquinolin-4-amine is a precursor for the synthesis of Rho kinase inhibitors. Rho kinase (ROCK) is a serine/threonine kinase that plays a critical role in the regulation of the actin cytoskeleton, cell contraction, migration, and proliferation. ROCK inhibitors are being investigated for the treatment of various diseases including cardiovascular diseases, neurological disorders, and cancer. The compound's isoquinoline core provides a scaffold for the development of kinase inhibitors that target the ATP-binding site of ROCK. The compound is also used in the synthesis of isoquinoline derivatives for the treatment of GLUT1 deficiency syndrome. GLUT1 deficiency syndrome is a genetic disorder characterized by impaired glucose transport into the brain, and modulators of GLUT1 are being explored as potential therapies. The compound's amino group allows for further derivatization to optimize target engagement and pharmacological properties.
|
|---|---|
| ln Vitro |
In vitro, isoquinolin-4-amine is used as a building block for the synthesis of Rho kinase inhibitors. It is also used in the synthesis of isoquinoline derivatives for the treatment of GLUT1 deficiency syndrome. The compound is a biochemical compound that may be utilized as a biomaterial or organic/chemical reagent for biomedical research. In medicinal chemistry, it serves as a scaffold for constructing biologically active molecules, particularly kinase inhibitors. Its isoquinoline core provides a rigid, planar structure that can interact with the ATP-binding sites of kinases through hydrogen bonding, hydrophobic interactions, and π-π stacking. The amino group at the 4-position allows for the introduction of various substituents to optimize potency, selectivity, and pharmacokinetic properties. In organic synthesis, the compound is used as a versatile building block for creating complex molecules efficiently.
|
| ln Vivo |
In vivo activity is mediated through the derivatives of isoquinolin-4-amine rather than the parent compound itself. Rho kinase inhibitors synthesized from this compound are evaluated in animal models of cardiovascular diseases, neurological disorders, and cancer. Isoquinoline derivatives for GLUT1 deficiency syndrome are evaluated in animal models of this genetic disorder. In these studies, compounds are typically administered orally or intraperitoneally to rodents, and parameters such as blood pressure, neurological function, tumor growth, and metabolic markers are assessed. The parent compound itself is not administered in vivo, as it is a synthetic intermediate rather than a pharmacological agent.
|
| Enzyme Assay |
Cell-free assays involving isoquinolin-4-amine are focused on its use as a chemical reagent in organic synthesis. Standard protocols for the synthesis of Rho kinase inhibitors involve coupling the compound with appropriate carboxylic acids or other electrophiles to form amides or other derivatives. The reaction progress is monitored by TLC or HPLC, and the products are purified by column chromatography. For kinase inhibition studies, the compound's derivatives are incubated with ROCK enzyme and a substrate, and kinase activity is measured using radioactive ATP or antibody-based detection. The compound's binding to ROCK can be studied using surface plasmon resonance or X-ray crystallography. Its use in the synthesis of GLUT1 modulators involves standard organic synthesis procedures.
|
| Cell Assay |
Cellular assays are not performed with the parent compound isoquinolin-4-amine. Instead, its derivatives, such as Rho kinase inhibitors and GLUT1 modulators, are evaluated in cell-based systems. For Rho kinase inhibitors, cell lines are treated with the derivatives, and ROCK activity, actin cytoskeleton organization, cell migration, and proliferation are assessed. For GLUT1 modulators, cells expressing GLUT1 are treated with the derivatives, and glucose uptake is measured. The parent compound itself is not used as a test article in cell-based experiments due to its role as a synthetic building block.
|
| Animal Protocol |
Animal studies are not conducted with the parent compound isoquinolin-4-amine. Its derivatives, such as Rho kinase inhibitors and GLUT1 modulators, are evaluated in animal models. For Rho kinase inhibitors, animal models of cardiovascular diseases, neurological disorders, or cancer are used. For GLUT1 modulators, animal models of GLUT1 deficiency syndrome are used. The parent compound itself is not administered to animals, as it is a synthetic intermediate. Toxicity and pharmacological profiles for the parent compound are inferred from related isoquinoline derivatives.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for isoquinolin-4-amine are not available, as the compound is primarily a synthetic intermediate rather than a drug candidate. With a molecular weight of 144.17 g/mol and a calculated LogP of 2.40, the compound is small and moderately lipophilic, suggesting that it would have moderate membrane permeability if administered. The compound has a topological polar surface area of 38.9 Ų. However, comprehensive pharmacokinetic studies including absorption, distribution, metabolism, and excretion have not been performed, as the compound is not intended for therapeutic use. For research purposes, the compound is typically handled as a neat chemical and not administered to living organisms for pharmacokinetic profiling.
|
| Toxicity/Toxicokinetics |
Toxicological data for isoquinolin-4-amine indicate that the compound is classified with GHS hazard statement H302 (harmful if swallowed). Precautionary statements include P264, P270, P280, P301+P312, P305+P351+P338, P330, P337+P313, and P501. The compound has a melting point of 360 °C and a boiling point of 360 °C at 760 mmHg. It appears as a white to dark brown powder and has a density of 1.21 g/cm³. Appropriate safety precautions should be taken when handling the compound, including the use of personal protective equipment such as gloves and safety goggles. The compound should be handled in a well-ventilated area, and contact with skin and eyes should be avoided.
|
| Additional Infomation |
Isoquinolin-4-amine is a research chemical, not an approved drug. It has no clinical trial or marketing approval status for therapeutic use. The compound is used for the synthesis of Rho kinase inhibitors and isoquinoline derivatives for the treatment of GLUT1 deficiency syndrome. It is a biochemical compound that may be utilized as a biomaterial or organic/chemical reagent for biomedical research. The compound has a molecular weight of 144.17 g/mol, a purity of 97%, and appears as a white to dark brown powder. It is classified with GHS hazard statement H302 (harmful if swallowed). The compound is for research use only and not for human use.
|
| Molecular Formula |
C9H8N2
|
|---|---|
| Molecular Weight |
144.17
|
| Exact Mass |
144.068
|
| CAS # |
23687-25-4
|
| PubChem CID |
90237
|
| Appearance |
Off-white to light brown solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
360.0±17.0 °C at 760 mmHg
|
| Melting Point |
107-113 °C
|
| Flash Point |
198.9±8.1 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.708
|
| LogP |
1.21
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
11
|
| Complexity |
136
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1C([H])=C(C2=C([H])C([H])=C([H])C([H])=C2C=1[H])N([H])[H]
|
| InChi Key |
ISIUXVGHQFJYHM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H8N2/c10-9-6-11-5-7-3-1-2-4-8(7)9/h1-6H,10H2
|
| Chemical Name |
isoquinolin-4-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.9363 mL | 34.6813 mL | 69.3626 mL | |
| 5 mM | 1.3873 mL | 6.9363 mL | 13.8725 mL | |
| 10 mM | 0.6936 mL | 3.4681 mL | 6.9363 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
